Therapeutics News and Research

RSS

Cancer Research Technology and The Institute of Cancer Research complete licence with Vernalis

Cancer Research Technology Limited (CRT) and The Institute of Cancer Research announce that Vernalis plc has licensed exclusive worldwide rights to an anti-cancer Hsp90 inhibitor programme.

29 Sep 2004

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

28 Sep 2004

Trial shows which brain cancer patients benefit from temozolomide

An international team of scientists and cancer specialists has identified which patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit.

28 Sep 2004

Researchers reveal potential new role for Glivec/Imatinib

Imatinib – or Glivec as it also known – looks as if it may become an effective treatment for yet another type of cancer.

28 Sep 2004

Arsenic trioxide - invented as a treatment for a rare type of leukaemia

Arsenic trioxide – a highly poisonous substance best known as an effective weed killer or pesticide and notorious for being a favourite ‘weapon’ of choice in murder mystery novels, is being re-invented as a treatment for a rare type of leukaemia.

28 Sep 2004

Guidant announces plans to initiate vulnerable plaque study

Guidant has announced plans to conduct a study designed to increase clinical understanding of “vulnerable” plaques – lipid-rich coronary lesions that suddenly rupture – that may cause most heart attacks.

27 Sep 2004

Stem cells from umbilical cord blood, given intravenously with mannitol drug reduce stroke size and damage

Researchers first gave the drug, mannitol, to provide temporary passage through the blood-brain barrier then transfused human umbilical cord blood cells into a stroke animal model. When used in the first hours and days following a stroke, stroke size decreased by 40 percent and resulting disability was significantly reduced.

26 Sep 2004

THC in marijuana may block the spread of forms of cancer causing herpes viruses

The compound in marijuana that produces a high, delta-9 tetrahydrocannbinol or THC, may block the spread of several forms of cancer causing herpes viruses, University of South Florida College of Medicine scientists report.

22 Sep 2004

Breakthrough in spinal regeneration research

University of Queensland researchers are claiming a breakthrough in spinal regeneration research with the discovery of a molecule that blocks regrowth of damaged nerve processes.

20 Sep 2004

ChemGenex discovers five new depression genes

ChemGenex Pharmaceuticals has announced that it has filed for patent protection for a further five novel depression-associated gene targets discovered by its depression and anxiety research group.

16 Sep 2004

Genetically modified bacterium as remedy for intestinal diseases

Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) at Ghent University are joining the fight against chronic intestinal disease with a genetically modified bacterium (Lactococcus lactis).

14 Sep 2004

Potential new drug for the treatment of sickle cell disease

The results were published in the June 2004 issue of The British Journal of Haematology (BJH). MX-1520 is a prodrug of vanillin, a very popular food additive generally regarded as safe (GRAS) by the FDA.

13 Sep 2004

Transthyretin discovery may halt progression of Alzheimer's

In a finding that may cause a dramatic shift in the way scientists and researchers search for a therapy for Alzheimer's disease, a team of researchers led by Jeff Johnson, an associate professor at the School of Pharmacy, has discovered that increased expression of a protein called transthyretin in the brain appears to halt the progression of the disease.

10 Sep 2004

Scientist rewarded for breaking down transplant rejection

A scientist from Australia's Monash University who has recently determined the structure of drug that is widely used as an immunosuppressant, will be presented the 2004 Science Minister's Prize for Life Scientist of the Year.

8 Sep 2004

Advances in gene silencing on the agenda

Recent advances in using 'RNA interference' (RNAi) to improve plant, animal and human health will be the major focus of the CSIRO-hosted Horizons in Livestock Sciences Conference on the Gold Coast from 12-15 September.

8 Sep 2004

Exubera shows sustained blood glucose control in patients with type 2 diabetes

New data showed that Exubera (inhaled insulin) was effective and well tolerated in controlling blood glucose levels over a two-year period in patients with Type 2 diabetes.

8 Sep 2004

Phico Therapeutics secures funding to tackle superbug

Phico Therapeutics Ltd, a Cambridge-based company that has developed a unique anti-bacterial technology to treat the hospital superbug, MRSA, has raised £550,000 with the help of Oxfordshire Investment Opportunity Network, Europe’s leading technology business angel network.

6 Sep 2004

Chemotherapy experts refute ASCO recommendations on use of drug sensitivity and resistance assays

A group of leading chemotherapy experts assembled as the Clinical Oncologists for Individualized Therapy (COFIT) refute the findings of the American Society of Clinical Oncology (ASCO) technology assessment panel regarding the use of chemotherapy sensitivity and resistance assays (CSRAs).

1 Sep 2004

Gene - beta1-integrin, could be key to breast cancer therapies

Canadian researchers at the Research Institute of the McGill University Health Centre and McMaster University have identified a new player in breast cancer. This gene, beta1-integrin, has been shown to be critical in the initiation of tumour growth and development in a mouse model of cancer.

30 Aug 2004

Study of new gene and cell therapy to better understand how genetically-engineered cells can help pace the heart

Guidant Corporation, Columbia University and Stony Brook University will collaborate to study a new gene and cell therapy that may ultimately provide better understanding of how genetically-engineered cells can help pace the heart.

26 Aug 2004